| Symbol | ENSC |
|---|---|
| Name | ENSYSCE BIOSCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | - |
| Address | 92037 United States CA 7946 Ivanhoe Avenue Suite 201 |
| Telephone | (858)263-4196 |
| Fax | — |
| — | |
| Website | https://ensysce.com/ |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001716947 |
| Description | Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Additional info from NASDAQ: Additional info from OTC: |
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Read moreNew Form S-8 - Ensysce Biosciences, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001493152-26-020504 <b>Size:</b> 295 KB
Read moreEnsysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Read moreNew Form EFFECT - Ensysce Biosciences, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 9999999995-26-001203 <b>Size:</b> 1 KB
Read moreEnsysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Read more(99% Neutral) ENSYSCE BIOSCIENCES INC. (ENSC) Announces Executive Departure
Read more(10% Negative) ENSYSCE BIOSCIENCES INC. (ENSC) Reports Q1 2026 Financial Results
Read moreEnsysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Read more(99% Neutral) ENSYSCE BIOSCIENCES INC. (ENSC) Announces Executive Changes
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06602271 | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | Phase3 | Postoperative Pain, Acute | Recruiting | 2025-12-09 | 2026-11-01 | ClinicalTrials.gov |
| NCT06500793 | Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With… | Phase1 | Pharmacokinetics | Recruiting | 2024-11-24 | 2026-12-31 | ClinicalTrials.gov |
| NCT06629402 | Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF6… | Phase2 | Acute Pain | Completed | 2023-10-05 | 2023-11-15 | ClinicalTrials.gov |
| NCT05571345 | A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreati… | Phase1 | Recreational Drug Use | Completed | 2022-10-05 | 2022-12-28 | ClinicalTrials.gov |
| NCT05567354 | A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Re… | Phase1 | Recreational Drug Use | Completed | 2022-06-10 | 2022-08-31 | ClinicalTrials.gov |
| NCT05090280 | Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-… | Phase1 | Pharmacokinetics | Completed | 2021-12-01 | 2023-04-26 | ClinicalTrials.gov |
| NCT05043766 | Evaluation of Oral PF614 Relative to OxyContin (PF614-102) | Phase1 | Healthy Volunteers | Completed | 2021-09-08 | 2022-03-21 | ClinicalTrials.gov |
| NCT04406415 | Oral Nafamostat in Healthy Volunteers (NAF-101) | Phase1 | Pharmacokinetics | Completed | 2020-09-21 | 2021-05-14 | ClinicalTrials.gov |
| NCT02454712 | Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) | Phase1 | Healthy | Completed | 2016-11-16 | 2018-01-18 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05571345 |
| Oxycodone Hydrochloride 40 mg | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05571345 |
| PF614 | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05571345 |
| Placebo | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05567354 |
| Oxycodone | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05567354 |
| PF614 | Other | Phase PHASE1 | Recreational Drug Use | COMPLETED | NCT05567354 |
| Nafamostat Mesylate | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05090280 |
| Naltrexone Hydrochloride | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05090280 |
| PF614 solution | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05090280 |
| OxyContin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05043766 |
| Naltrexone Hydrochloride | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05043766 |
| PF614 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05043766 |
| Placebo | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04406415 |
| Nafamostat Mesilate | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT04406415 |
| Naltrexone Hydrochloride | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02454712 |
| Oxycodone extended-release | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02454712 |
| PF614 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02454712 |
| Placebo | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06629402 |
| PF614 | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06629402 |
| Placebo | Other | Phase PHASE3 | Postoperative Pain, Acute | RECRUITING | NCT06602271 |
| PF614 capsule | Other | Phase PHASE3 | Postoperative Pain, Acute | RECRUITING | NCT06602271 |
| Nafamostat Mesylate | Other | Phase PHASE1 | Pharmacokinetics | RECRUITING | NCT06500793 |
| PF614 capsule | Other | Phase PHASE1 | Pharmacokinetics | RECRUITING | NCT06500793 |